CTLA-4 Checkpoint

CTLA-4 (Cytotoxic T-Lymphocyte Associated protein 4) is one well-known immune checkpoint protein. Drugs such as Yervoy (ipilumimab), which is FDA approved in melanoma, target the CTLA-4 receptor. These drugs are currently being studied in clinical trials for lung cancer and may work particularly well when used with PD-L1 checkpoint inhibitors. These combinations are being studied in both small cell and non-small cell lung cancer.